Cargando…
Onset of secondary progressive MS after long‐term rituximab therapy – a case report
A patient with relapsing multiple sclerosis (RMS) was treated with a standard immunomodulatory therapy, but due to ongoing disease activity was switched to rituximab. Relapses ceased, but secondary progressive MS (SPMS) eventually appeared, associated with new focal spinal cord white matter lesions....
Autores principales: | von Büdingen, H.‐Christian, Bischof, Antje, Eggers, Erica L., Wang, Shengzhi, Bevan, Carolyn J., Cree, Bruce A. C., Henry, Roland G., Hauser, Stephen L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5221476/ https://www.ncbi.nlm.nih.gov/pubmed/28078314 http://dx.doi.org/10.1002/acn3.377 |
Ejemplares similares
-
Rituximab before and during pregnancy: A systematic review, and a case series in MS and NMOSD
por: Das, Gitanjali, et al.
Publicado: (2018) -
Simultaneous assessment of regional distributions of atrophy across the neuraxis in MS patients
por: Freund, Patrick, et al.
Publicado: (2022) -
A Haystack Heuristic for Autoimmune Disease Biomarker Discovery Using Next-Gen Immune Repertoire Sequencing Data
por: Apeltsin, Leonard, et al.
Publicado: (2017) -
Rituximab, MS, and pregnancy
por: Smith, Jessica B., et al.
Publicado: (2020) -
Reply to “Spinal Cord Atrophy Is a Preclinical Marker of Progressive MS”
por: Bischof, Antje, et al.
Publicado: (2022)